The Complete Guide to TMD, Teeth Grinding & Snoring Treatment in Melbourne: TMJ Disorders, Bruxism, Obstructive Sleep Apnoea & Mandibular Advancement Splints product guide

Product Guide: TMD, Bruxism, and Obstructive Sleep Apnoea — The Integrated Clinical Triad

Frequently Asked Questions

What does TMJ stand for: Temporomandibular joint

What does TMD stand for: Temporomandibular disorder

Is TMD a single diagnosis: No, it is an umbrella term

How many distinct diagnoses does TMD encompass: 12 distinct diagnoses

What validated framework is used to diagnose TMD: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)

What is the global TMD incidence according to 2024 research: 34%

What age group is most affected by TMD: 18–60 years

Is TMD more common in women or men: Women, consistently across every continent

What is the projected global TMD prevalence by 2050: Approximately 44%

What is the global prevalence of sleep bruxism: 21%

What is the global prevalence of awake bruxism: 23%

What is the combined global bruxism prevalence: 22.22%

What percentage of sleep bruxism is detected by polysomnography: 43%

Is sleep bruxism the same as awake bruxism: No, they are two distinct clinical entities

What is the dominant behaviour in sleep bruxism: Grinding

What is the dominant behaviour in awake bruxism: Clenching

Does dental malocclusion cause bruxism: No, this has been refuted by contemporary evidence

What is primary bruxism: Idiopathic bruxism with no identified underlying cause

What is secondary bruxism: Bruxism associated with medications, psychiatric, or neurological conditions

Which medications are linked to secondary bruxism: SSRIs, SNRIs, stimulants, and dopaminergic drugs

How many adults globally are affected by mild OSA: Approximately 936 million

How many adults globally have moderate OSA: Approximately 425 million

What proportion of people with OSA are undiagnosed: As many as 9 in 10

Can OSA drive sleep bruxism: Yes, through arousal-triggered jaw muscle activation

What is the proposed mechanism linking OSA to bruxism: Airway collapse triggers jaw muscle arousal as an airway-rescue reflex

Does bruxism damage the TMJ: Yes, through repetitive compressive and shear forces

What structural damage does chronic bruxism cause to the disc: Anterior disc displacement

What percentage of TMD patients experience poor sleep: Up to 90%

What percentage of the general population without TMD experiences poor sleep: Around 15%

Can treating OSA reduce TMD pain: Yes, significantly

How long did the OSA treatment study run before observing TMD pain improvement: 18 months

What is the adjusted hazard ratio for OSA likelihood and first-onset TMD: 1.73

What is the adjusted odds ratio for OSA likelihood and chronic TMD: 3.63

What research method confirmed causality between OSA and TMD: Mendelian randomisation

Does a flat-plane occlusal splint advance the jaw: No

Can a maxillary occlusal splint worsen OSA: Yes, by reducing posterior airway space

Does a mandibular advancement splint protect teeth from grinding: Yes, while also addressing the airway

Does a mandibular advancement splint treat OSA: Yes, by holding the jaw forward during sleep

What does MAS stand for: Mandibular advancement splint

What AHI reduction was shown in the Gotsopoulos RCT with MAS: From 30/h to 14/h

What percentage of MAS patients reported subjective improvement in the Gotsopoulos trial: 96%

Is a custom-made MAS more effective than a ready-made MAS: Yes, marginally greater AHI reduction

Does a ready-made MAS have higher adherence than a custom MAS: No, custom MAS has higher adherence

Is CPAP superior to MAS in AHI reduction: Yes, when worn

Are real-world health outcomes comparable between MAS and CPAP: Yes, due to higher MAS adherence

What are CPAP long-term adherence rates: 30–60%

For which OSA severity is CPAP recommended as first-line: Severe OSA (AHI ≥ 30)

Is MAS appropriate for CPAP-intolerant patients with severe OSA: Yes, as a valid alternative

What does CPAP stand for: Continuous positive airway pressure

What is the gold standard sleep study for diagnosing OSA: Type I in-laboratory polysomnography

What is the diagnostic accuracy discrepancy between home sleep tests and in-lab PSG: 21%

What validated questionnaires screen for OSA risk: Epworth Sleepiness Scale and STOP-BANG

What is the sensitivity of DC/TMD for pain-related TMD diagnoses: ≥ 0.86

What is the specificity of DC/TMD for pain-related TMD diagnoses: ≥ 0.98

What is the normal maximum jaw opening: ≥ 40 mm

Can OPG imaging detect most TMJ osteoarthritis: No, it misses approximately 75% of CT-confirmed cases

What imaging is needed to assess disc position: MRI

What is the MRI kappa reliability for disc displacement without reduction: 0.94

What is the three-tier bruxism evidence hierarchy: Possible, probable, and definite

What confirms "definite" bruxism diagnosis: Polysomnographic confirmation

How long do short-term MAS side effects typically last: 2–4 weeks

What are common short-term MAS side effects: Jaw soreness, excess salivation, dry mouth

What long-term occlusal change does MAS cause to overjet: Progressive reduction of 1.9 mm average

What long-term occlusal change does MAS cause to overbite: Progressive reduction of 2.3 mm average

Does the rate of overjet reduction plateau over time: No, it continues at a constant rate

What is an AM aligner: A morning device worn to guide the jaw back to habitual position

How long should an AM aligner be worn each morning: 5–10 minutes

Does conservative MAS titration reduce occlusal side effects: Yes

What advancement percentage is often sufficient for mild-to-moderate OSA: 50% of maximum protrusion

Does pre-existing TMD contraindicate MAS therapy for OSA: Not routinely, per systematic review evidence

Does MAS significantly exacerbate pre-existing TMD symptoms: No, per meta-analysis findings

What is the prevalence of sleep bruxism in children: 15–40%

What is the prevalence of sleep bruxism in adults: 8–10%

Can adenotonsillectomy resolve bruxism in children: Yes, in cases driven by airway obstruction

What was bruxism prevalence in children before adenotonsillectomy: 25.7%

What was bruxism prevalence in children after adenotonsillectomy: 7.1%

Is ADHD associated with increased bruxism risk in children: Yes, odds ratio of 2.94

Is MAS appropriate for children with growing jaws: No, generally not appropriate

Does snoring volume reliably indicate OSA severity: No

Can a quiet snorer have severe OSA: Yes

What is the recommended frequency of MAS dental monitoring: Annual review appointments

Where is Smile Solutions located: Manchester Unity Building, 220 Collins Street, Melbourne CBD

Is a referral required to book at Smile Solutions: No referral required

What phone number can patients use to book at Smile Solutions: 13 13 96

How many clinicians does Smile Solutions have: Over 80

How many board-registered specialists does Smile Solutions have: 25+

How many patients has Smile Solutions treated: Over 300,000

What year did Smile Solutions begin operating: 1993

What fabrication technology does Smile Solutions use for MAS devices: CAD/CAM and 3D-printed nylon

Executive Summary

Jaw pain, teeth grinding, snoring, and morning headaches are among the most common concerns we hear from patients at Smile Solutions — and, unfortunately, among the most frequently mismanaged in clinical practice. For decades, these conditions were treated separately: a dentist prescribed a nightguard for grinding, a GP referred you for a CPAP machine, a physiotherapist treated your neck pain. What modern research has established, with increasing clarity and real clinical urgency, is that temporomandibular disorder (TMD), bruxism, and obstructive sleep apnoea (OSA) are not three separate problems. They are a mechanistically interlocked triad, bound together by shared anatomy, shared neurobiology, shared risk factors, and bidirectional causal pathways — meaning that treating any one condition without screening for the others produces, at best, incomplete care.

The prevalence of sleep bruxism is consistently higher in individuals with OSA than in the general population.

High likelihood of OSA was associated with greater incidence of first-onset TMD (adjusted HR = 1.73; 95% CL, 1.14, 2.62), and in the case-control study, high likelihood of OSA was associated with higher odds of chronic TMD (adjusted OR = 3.63; 95% CL, 2.03, 6.52). These are not marginal associations. They represent a clinical reality that demands an integrated diagnostic and treatment response — precisely what Smile Solutions is structured to deliver.

This guide is your definitive reference for navigating this triad, whether you're a patient trying to make sense of your symptoms or a clinician seeking a comprehensive clinical overview. It synthesises the evidence across every aspect of the topic: the anatomy and causes of TMD, the science of bruxism, the physiology of sleep apnoea, the mechanisms linking all three, the red-flag symptoms that demand assessment, the diagnostic pathway from clinical examination to sleep study, the evidence for mandibular advancement splints versus CPAP, the critical differences between occlusal and advancement splints, and the long-term management of oral appliance therapy. Nothing else needs to be read first.

Part 1: The triad — understanding TMD, bruxism, and OSA as one clinical entity

What is TMD? The anatomy and the spectrum

Your temporomandibular joints (TMJ) are among the most biomechanically complex joints in the human body. They are the only paired joints that must function in synchrony, and they perform hundreds of movements every day in the service of chewing, speaking, and swallowing. When this architecture is disrupted — through muscle hyperactivity, disc displacement, joint inflammation, or structural degeneration — the result is temporomandibular disorder (TMD).

"TMD" is not a single diagnosis. It is an umbrella term for a spectrum of conditions affecting the masticatory muscles, the temporomandibular joints, and associated structures. The internationally validated Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) recognises 12 distinct diagnoses, grouped into painful conditions (myalgia, arthralgia, headache attributed to TMD) and non-painful conditions (disc displacements, degenerative joint disease, subluxation). You may carry multiple simultaneous diagnoses — and those diagnoses may evolve as your condition progresses or resolves.

The scale of the problem is significant. A 2024 meta-analysis published in the Journal of Clinical Medicine found a global TMD incidence of 34%, with the 18–60 age group most affected and women consistently more affected than men across every continent studied. Research published in 2025 projects that by 2050, global TMD prevalence may approach 44%, driven by population ageing, rising stress levels, and increasing rates of sleep-disordered breathing — all established risk factors. (For a foundational deep-dive into TMD anatomy, diagnostic categories, and the full symptom spectrum, see our detailed guide on What Is TMD? Understanding Temporomandibular Joint Disorders, Causes, and Symptoms.)

What is bruxism? Two conditions, not one

Bruxism — the repetitive clenching, grinding, and bracing of the jaw — is one of the most prevalent oral conditions in the world. The global bruxism (sleep and awake) prevalence is 22.22%, with global sleep bruxism prevalence at 21% and awake bruxism prevalence at 23%.

The occurrence of sleep bruxism, based on polysomnography, was estimated at 43% — a figure that reflects how much sleep bruxism goes undetected by self-report alone.

The most clinically important distinction in all of bruxism science is the separation of sleep bruxism (SB) and awake bruxism (AB) into two distinct clinical entities with different neurobiological mechanisms, different dominant behaviours (grinding vs. clenching), and different treatment implications. Sleep bruxism is a sleep-related movement disorder regulated by the central nervous system and closely linked to sleep microarousals; awake bruxism is semi-voluntary, stress-reactive, and strongly associated with anxiety and habitual jaw-bracing during the day.

Beyond the sleep/awake distinction, bruxism is further categorised as primary (idiopathic) or secondary — the latter associated with psychiatric or neurological conditions, or with medications including SSRIs, SNRIs, stimulants, and dopaminergic drugs. This distinction is not academic: in secondary bruxism, treating the underlying cause is a primary therapeutic step. In primary bruxism, management focuses on protection and risk factor reduction.

What does not cause bruxism — despite decades of dental mythology — is dental malocclusion. Previously held notions that attributed occlusal discrepancies as singular aetiologic determinants have been refuted by contemporary evidence. This is why "adjusting the bite" to treat bruxism is not supported as a primary intervention. (For the complete science of bruxism — causes, types, and the progressive damage it produces — see our guide on Bruxism Explained: Causes, Types, and the Hidden Dangers of Teeth Grinding.)

What is OSA? The airway anatomy that makes this a dental concern

Obstructive sleep apnoea is a sleeping and breathing disorder characterised by recurrent complete (apnoeas) and partial (hypopnoeas) upper airway obstruction during sleep, resulting in intermittent hypoxaemia, autonomic fluctuation, and sleep fragmentation. It is not simply a snoring problem. It is a structural problem — and the structures involved are directly within your dentist's clinical domain.

The pharyngeal airway has no skeletal framework, leaving it highly susceptible to collapse of surrounding soft tissues. Your mandible (lower jaw), tongue, soft palate, and lateral pharyngeal walls all determine airway geometry during sleep — and all fall within the clinical purview of a thorough dental examination. A receding lower jaw, a posteriorly positioned tongue, a high-arched palate, or scalloped tongue margins are all observable during a routine dental assessment, and all are established anatomical risk factors for OSA.

OSA is associated with multiple cardiovascular, metabolic, and neurocognitive comorbidities that affect your health and quality of life. Its global burden is staggering: approximately 936 million adults aged 30–69 are affected by mild OSA, whilst about 425 million have moderate forms — and as many as 9 in 10 people with OSA do not know they have it. (For a complete explanation of OSA pathophysiology, AHI severity classification, and systemic health consequences, see our guide on Obstructive Sleep Apnoea: What It Is, Why It Happens, and Why Your Dentist Can Help.)

Part 2: The mechanistic links — why these three conditions amplify each other

How airway collapse drives teeth grinding

The most clinically important directional relationship in this triad — and the one most commonly missed — is the role of OSA as a driver of sleep bruxism. Sleep bruxism is characterised by rhythmic masticatory muscle activity (RMMA), and temporomandibular disorders are frequently related to sleep disorders such as poor sleep quality, insomnia, sleep apnoea, and bruxism. Evidence from multiple studies indicates worse sleep quality and increased pain sensitivity in TMD patients, with degenerative joint changes associated with stress and poor sleep.

The mechanism is now well-characterised: when your breathing stops during an apnoeic event, your brain triggers arousal signals that stimulate the jaw muscles, leading to teeth grinding or clenching as a reflexive response to shift the jaw forward and reopen the airway. Fluctuations in serotonin, dopamine, and opioid release can induce rhythmic movements of the masticatory muscles, facilitating mandibular protrusion and airway opening. In this framing, sleep bruxism in a patient with OSA may represent the body's own airway-rescue mechanism — a biological attempt to thrust the mandible forward and reopen the collapsed pharyngeal airway.

This reframes the clinical picture entirely. If you're presenting with worn teeth and jaw pain, you may not simply have a "stress grinding habit." You may have an undiagnosed airway disorder that is driving the grinding as a survival reflex night after night.

How bruxism damages the TMJ

The directional relationship also runs the other way: chronic bruxism is a well-established pathway to TMD. Sleep-related bruxism, a common feature of OSA, involves involuntary teeth grinding during sleep and has been proposed as a contributing factor to TMD symptoms. The increased muscle activity associated with bruxism leads to increased stress on the temporomandibular joint and surrounding structures, potentially driving the development of TMD symptoms.

The structural consequences are cumulative and progressive: repetitive compressive and shear forces displace the articular disc anteriorly; chronic overloading of the condyle causes bony remodelling visible on CBCT imaging; sustained contraction of the masseter, temporalis, and pterygoid muscles produces myofascial pain and temporal headaches; and progressive tooth wear alters the bite relationship, changing the resting position of the mandible and the loading of the TMJ.

The pain-sleep amplification loop: the engine of chronicity

Perhaps the most under-appreciated mechanism linking all three conditions is the bidirectional relationship between pain and sleep quality. Sleep disturbances aggravate pain through the descending pain modulation system, central sensitisation, and increased inflammation. Elevated cortisol levels due to stress — which can by itself interfere with sleep — have also been found in untreated patients with TMD and sleep bruxism.

When OSA fragments your sleep architecture, it disrupts the restorative stages during which pain-inhibitory systems recover and inflammatory cytokines are cleared. The result is central sensitisation — a state of amplified pain processing in which your nervous system becomes hyperresponsive to nociceptive input. This is why many TMD patients report that their jaw pain is worst in the morning and improves through the day.

The clinical proof of this mechanism is compelling. The bidirectional relationship between poor sleep and pain intensity has been well studied, and good sleep quality has been identified as a key factor underlying pain control. A prospective cohort study examined whether OSA treatment reduces TMD pain and headache attributed to TMD in patients with OSA after 18 months of treatment, and at follow-up, significant improvements in the intensity of pain-related TMD and headache attributed to TMD were observed (p < 0.05).

This finding has a direct clinical implication: treating OSA can directly reduce your TMD pain — not by addressing the joint itself, but by restoring the sleep quality that underpins normal pain regulation.

The Mendelian evidence: causality, not just correlation

A 2024 study investigated the bidirectional causal relationship between obstructive sleep apnoea and temporomandibular disorders using an online pooled dataset of genome-wide association studies (GWAS) and a two-sample bidirectional Mendelian randomisation method. Mendelian randomisation uses genetic variants as instrumental variables to test causal relationships, overcoming the confounding limitations of observational studies. Applying this methodology to the OSA-TMD relationship represents a meaningful advance in establishing causality — not merely association — between these conditions.

Shared risk factors: why these conditions cluster together

Obesity, craniofacial morphology, and sleep-related bruxism have been proposed as mechanisms contributing to the OSA-TMD association. Beyond direct mechanistic causation, the three conditions share a constellation of biological and psychosocial vulnerabilities — psychological stress and anxiety, sympathetic nervous system dysregulation, dopaminergic and serotonergic dysregulation, poor sleep quality, and retrognathic jaw anatomy — that explain why they so frequently co-present in the same patient.

The sympathetic nervous system plays a central role: the increased stimulation of the sympathetic nervous system observed in OSA underlies an increased prevalence of TMD, with individuals who are genetically predisposed to an increased sensitivity to catecholamines at increased risk of developing first-onset TMD.

(For the complete mechanistic analysis of how these three conditions interact, including the severity gradient in bruxism across OSA severity levels and the clinical implications for treatment sequencing, see our guide on The TMD-Bruxism-Sleep Apnoea Connection: How Jaw, Teeth, and Airway Problems Are Linked.)

Part 3: Recognising the triad — red-flag symptoms that demand assessment

Why symptoms are routinely missed

The challenge with TMD, bruxism, and OSA is that each condition produces symptoms that overlap with dozens of other health conditions. A morning headache might be attributed to dehydration. Jaw soreness might be dismissed as stress. Snoring might be accepted as a family trait. Worn teeth might be attributed to diet. This symptom dispersal means you may consult multiple practitioners — a GP for fatigue, a physiotherapist for neck pain, a dentist for tooth sensitivity — without any single clinician assembling the complete picture.

Sleep disturbances are highly prevalent amongst those with TMD, with up to 90% of patients experiencing poor sleep compared to around 15% of the population without TMD. Despite this, the connection between jaw dysfunction and sleep disorder is rarely made in primary care.

The red-flag symptom clusters

A single symptom rarely demands urgent specialist evaluation, but certain symptom combinations almost always do. The following clusters should prompt you to seek professional assessment:

Cluster 1 — Morning predominance pattern (high OSA/bruxism suspicion):

• Headaches present upon waking that resolve within 30–60 minutes
• Jaw soreness or stiffness that improves through the day
• Unrefreshing sleep despite adequate duration
• Partner-reported snoring, gasping, or grinding sounds

Cluster 2 — Jaw and joint symptom pattern (high TMD suspicion):

• Clicking, popping, or crepitus in the TMJ on opening or closing
• Jaw pain provoked by chewing, yawning, or prolonged talking
• Restricted or deviated jaw opening
• Recurring earache with consistently normal ear examination findings

Cluster 3 — Dental evidence pattern (high bruxism suspicion):

• Flattened, polished wear facets on multiple teeth
• Premature fracturing of restorations (crowns, veneers, fillings)
• Scalloped tongue margins or buccal mucosa ridging
• Masseter muscle hypertrophy visible on facial examination

Cluster 4 — Sleep and fatigue pattern (high OSA suspicion):

• Persistent daytime fatigue not explained by lifestyle factors
• Difficulty concentrating or memory problems
• Loud snoring audible through closed doors
• Witnessed breathing pauses or choking episodes

Research published in Scientific Reports (2025) found that in patients with confirmed TMD, sleep bruxism was correlated with several clinical and sleep-related factors, including TMJ noise (r = 0.52), TMD pain (r = 0.48), craniomandibular index (r = 0.32), limited mouth opening (r = 0.29), and tinnitus (r = 0.29). These correlations mean that jaw clicking and TMJ pain are not just symptoms of TMD — they are reliable predictors of co-existing sleep bruxism.

(For the complete symptom guide including specific red-flag thresholds for each symptom category and the structured assessment checklist, see our guide on Recognising the Signs: When Jaw Pain, Headaches, Snoring, and Grinding Mean You Need Assessment.)

Part 4: The diagnostic pathway — from clinical examination to sleep study

Why diagnosis precedes device selection

Getting a mouthguard fabricated without a proper diagnosis is one of the most common — and consequential — mistakes in the management of jaw pain, teeth grinding, and snoring. A flat-plane occlusal splint prescribed for a patient whose grinding is actually driven by undiagnosed OSA may suppress the grinding symptom whilst leaving the underlying airway collapse untreated. Conversely, a mandibular advancement splint (MAS) fitted without a prior assessment of the TMJ can worsen an existing disc displacement. In both cases, the device is not wrong — the diagnosis is incomplete.

Stage 1: Structured clinical examination using DC/TMD

The clinical examination for TMD is not a subjective art. Since 2014, the internationally validated Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) has provided a dual-axis framework for both clinical and research settings, with sensitivity ≥ 0.86 and specificity ≥ 0.98 for pain-related TMD diagnoses.

A DC/TMD-compliant clinical examination includes: pain history (location, duration, provocation); jaw range of motion measurement (normal maximum opening ≥ 40 mm); muscle palpation of the temporalis and masseter; joint noise assessment; and occlusal analysis for bruxism-related wear patterns. Axis II questionnaires assess the psychosocial and behavioural factors that significantly affect TMD management.

Bruxism is graded along a three-tier evidence hierarchy: "possible" (self-report alone), "probable" (self-report plus clinical examination findings), and "definite" (polysomnographic confirmation). Clinical markers are useful screening tools but cannot replace objective sleep testing for definitive diagnosis.

A complete assessment also includes structured screening for sleep-disordered breathing using validated questionnaires — including the Epworth Sleepiness Scale (ESS) and STOP-BANG questionnaire — before any decision about sleep study referral.

Stage 2: TMJ imaging — choosing the right modality

Clinical examination alone has a significant ceiling for intra-articular disorders. The imaging modality chosen depends on what the clinical picture demands:

CBCT cannot provide precise information related to disc position. MRI is needed when soft tissue lesions of the TMJ are suspected, and performs well for disc displacement diagnosis: using MRI, reliability was excellent for diagnosing disc displacement with reduction (kappa = 0.78) and without reduction (kappa = 0.94).

Stage 3: Sleep study — confirming OSA and detecting sleep bruxism

The AASM/AADSM Clinical Practice Guideline recommends that sleep physicians conduct follow-up sleep testing to confirm treatment efficacy, rather than conduct follow-up without sleep testing, for patients fitted with oral appliances.

A mandibular advancement splint fabricated without a prior sleep study carries significant clinical risk. Without a baseline AHI, there is no way to confirm whether the device has achieved therapeutic efficacy — and you continue to experience the cardiovascular and metabolic consequences of untreated apnoea.

In-laboratory, overnight Type I polysomnography (PSG) is the gold standard for diagnosing OSA and simultaneously detecting sleep bruxism through masseter and temporalis EMG channels. Home sleep apnoea testing (HSAT) offers better comfort and lower cost, but a meta-analysis revealed a discrepancy of 21% between the AHI correlation and diagnostic accuracy of home sleep apnoea tests compared to in-lab PSG.

(For the complete diagnostic pathway — from structured clinical examination through advanced imaging and sleep study methodology — see our guide on How TMD, Bruxism, and Sleep Apnoea Are Diagnosed: From Clinical Exam to Sleep Study.)

Part 5: Treatment — the evidence-based spectrum

The critical device decision: occlusal splint vs. mandibular advancement splint

The decision between a flat-plane occlusal splint and a mandibular advancement splint (MAS) is the single most consequential clinical decision in the management of bruxism — and the one most frequently made without adequate diagnostic information.

A flat-plane occlusal splint is a custom-fabricated hard acrylic device that redistributes bite forces across a sacrificial surface, provides sensorimotor feedback, and reduces masticatory muscle loading. It is the most evidence-supported conservative intervention for myofascial TMD pain. However, the Cochrane systematic review found there is insufficient evidence to either support or refute the use of occlusal splints for treating sleep bruxism itself — they protect teeth but do not reliably reduce the underlying grinding behaviour.

More critically: wearing a maxillary occlusal splint may be associated with a risk of aggravating obstructive sleep apnoea. By increasing vertical dimension without advancing the mandible, the splint can posteriorly rotate the jaw and reduce the posterior airway space — the opposite of what is needed if you have OSA.

A mandibular advancement splint addresses both the airway and the occlusal surface simultaneously. When the MAS addresses airway obstruction, it may simultaneously reduce the arousal-driven grinding episodes that are secondary to obstructive events. In a cohort study of 38 OSA patients, the RMMA index decreased significantly with both CPAP and mandibular advancement appliance therapies (p < 0.05).

The clinical decision framework is clear:

(For the complete evidence-based comparison of these two devices — including the airway safety data, material science, and the diagnostic logic that determines which device is right for which situation — see our guide on Occlusal Splints vs. Mandibular Advancement Splints for Bruxism: Choosing the Right Device.)

Mandibular advancement splints: how they work and what to expect

A mandibular advancement splint is a prescription custom-made medical device that works by holding your lower jaw in a forward (protruded) position during sleep, physically tethering the tongue and associated soft tissues away from the posterior pharyngeal wall. This prevents the airway collapse that characterises OSA and produces the vibration of snoring.

The evidence for MAS efficacy is robust. In a landmark randomised controlled trial published in the American Journal of Respiratory and Critical Care Medicine (Gotsopoulos et al., 2001), subjective improvements with the MAS were reported by the majority of patients (96%), with significant improvements in AHI (30 ± 2/h versus 14 ± 2/h, p < 0.0001), minimum oxygen saturation, and arousal index compared with the control.

A 2025 systematic review published in the American Journal of Orthodontics and Dentofacial Orthopedics confirmed that custom-made MADs showed marginally greater AHI reduction than ready-made MADs, have longer wearing times and higher adherence rates, and generally have fewer side effects than ready-made MADs. Pre-fabricated, off-the-shelf appliances are not clinically appropriate as either a therapeutic option or a screening tool.

A 2025 systematic review found that across included studies, MADs consistently reduced AHI from baseline and improved ESS and/or snoring. In head-to-head comparisons, MADs generally yielded smaller reductions in AHI than CPAP but achieved comparable improvements in symptoms and quality of life, with higher nightly adherence.

Titration — the incremental advancement of the mandibular position until the therapeutic optimum is reached — is the most important phase of MAS therapy. MAS efficacy is directly related to the amount of mandibular advancement, and optimal advancement is highly individual and cannot be set arbitrarily. Following titration, a follow-up sleep study performed with the device in situ is non-negotiable — subjective improvement alone is insufficient to confirm that OSA has been adequately controlled.

(For the complete MAS guide — mechanism of action, CAD/CAM fabrication, titration protocol, and realistic outcome expectations — see our guide on Mandibular Advancement Splints Explained: How They Work, Who They're For, and What to Expect.)

MAS vs. CPAP: the evidence-based comparison

CPAP (Continuous Positive Airway Pressure) delivers a constant stream of pressurised air through a mask, creating a pneumatic splint that prevents airway collapse. It achieves superior AHI reduction compared to MAS when worn. However, the clinical reality of CPAP is that adherence rates range from only 30–60% long-term — meaning the superior efficacy on paper is frequently not realised in practice.

In head-to-head comparisons, MADs generally yielded smaller reductions in AHI than CPAP but achieved comparable improvements in symptoms and quality of life, with higher nightly adherence. A landmark randomised crossover trial confirmed that despite CPAP's superior AHI reduction, important health outcomes were similar after one month of optimal MAD and CPAP treatment — the greater efficacy of CPAP being offset by inferior compliance relative to MAD, resulting in similar effectiveness.

The AASM/AADSM 2015 Clinical Practice Guideline recommends MAS for patients who need treatment for primary snoring, for patients with mild-to-moderate OSA who prefer an alternative to CPAP, and for patients with OSA who are intolerant to CPAP. There is general consensus that patients with severe OSA (AHI ≥ 30) should receive CPAP as first-line therapy, though MAS remains a valid alternative for those who cannot tolerate CPAP.

Meta-regression analysis showed that patients with pre-existing signs and symptoms of TMD do not experience significant exacerbation of symptoms using the MAD. The presence of TMD does not appear to be a routine contraindication for the use of MAD for the management of OSA. This is a clinically important finding: mild-to-moderate TMD does not preclude MAS therapy, though active, severe TMD requires careful evaluation.

(For the complete evidence-based comparison — including compliance data, quality-of-life outcomes, cost considerations, and the combination MAS + CPAP approach — see our guide on Mandibular Advancement Splint vs. CPAP: Which Sleep Apnoea Treatment Is Right for You?.)

TMD treatment: the full conservative-first spectrum

TMD management extends well beyond oral appliance therapy. The evidence supports a conservative-first, cause-targeted approach that may include:

Tier 1 — Patient education and self-care: Dietary modification (avoiding hard foods during flare-ups), jaw rest, heat/cold therapy, postural correction, and stress management form the foundation of TMD management. These strategies are not passive — they are active interventions with measurable impact.

Tier 2 — Occlusal splints: Hard flat-plane stabilisation splints are the most widely prescribed TMD treatment globally, with evidence supporting pain reduction in myofascial TMD. However, a 2024 Cochrane systematic review of 57 RCTs found that there is little or no clear evidence that occlusal splints are superior to physiotherapy in treating TMDs — in long-term follow-up, they were equally effective as other therapies. Splints are valuable tools but not standalone cures.

Tier 3 — Jaw physiotherapy: A 2023 umbrella meta-meta-analysis published in the Journal of Clinical Medicine (Arribas-Pascual et al.) pooling 31 systematic reviews found moderate effects for manual therapy and therapeutic exercise, and large effects for low-level laser therapy on improving pain intensity and maximum mouth opening in patients with TMD. Physiotherapy is consistently underutilised in patients who receive only a splint.

Tier 4 — Pharmacological support: NSAIDs, muscle relaxants, and low-dose tricyclic antidepressants play supporting roles in managing acute pain and enabling engagement with physiotherapy — but do not constitute primary treatment.

Tier 5 — Botulinum toxin (Botox) for refractory cases: A landmark 2024 systematic review and meta-analysis (Li et al., Journal of Oral Rehabilitation), encompassing 15 RCTs and 504 participants, found that BTX-A was significantly more effective than placebo in reducing TMD pain intensity at 1 month and 6 months. Injections at the masseter, temporalis, and pterygoid muscles were linked to the greatest pain reduction.

(For the complete TMD treatment spectrum with full evidence grading for each modality, see our guide on TMD Treatment Options in Melbourne: Splints, Physiotherapy, Botox, and Beyond.)

Part 6: Long-term management — what you need to know

The progressive nature of MAS side effects

MAS therapy is not a "fit and forget" intervention. Because OSA is a chronic condition requiring lifelong management, MAS therapy may span a decade or more — and the side effect profile evolves with duration.

Short-term side effects (jaw soreness, excess salivation, dry mouth, transient morning bite changes) are common and typically resolve within the first 2–4 weeks of use. They are expected, manageable, and rarely a reason to discontinue therapy.

Long-term side effects are more significant. The landmark Pliska et al. (2014) study in the Journal of Clinical Sleep Medicine — a retrospective analysis of 77 patients treated with MAS for an average of 11.1 years — found significant progressive reductions in overbite (2.3 ± 1.6 mm), overjet (1.9 ± 1.9 mm), and mandibular crowding (1.3 ± 1.8 mm). The reduction in overjet is progressive and continues at a constant rate as long as MAS treatment continues, a logical finding given that the main mechanism of action with a MAS is the protrusion of the mandible and associated soft tissues. As long as this continues to occur, forces will also continue to be applied to the teeth resulting in tooth movement.

A 2025 meta-analysis (Chen et al., Journal of Prosthodontics) confirmed long-term OA treatment is associated with a significant decrease in overbite (0.87 mm) and overjet (0.86 mm), with retroclination of upper incisors and proclination of lower incisors — all progressive with treatment duration.

The limited available evidence suggests that mandibular advancement splint therapy for snoring and obstructive sleep apnoea results in changes in craniofacial morphology that are predominantly dental in nature, especially on a long-term basis. Given the chronic nature of obstructive sleep apnoea and that oral appliance use may be a lifelong treatment, thorough customised follow-up should be undertaken to detect possible side effects on the craniofacial complex.

Mitigation strategies that work

The evidence supports practical strategies to reduce the rate and severity of occlusal change:

1. Conservative titration: Research shows that in most patients with mild-to-moderate OSA, advancement of 50% of maximum protrusion is equally as effective as 75% — the "less is more" principle that meaningfully reduces long-term occlusal change.
2. Morning jaw exercises: The AADSM recommends structured morning jaw exercises as first-line management for bite changes. Isometric and passive jaw stretching exercises have been shown to decrease discomfort and improve adherence to oral appliance therapy.
3. Morning occlusal guide (AM aligner): A small thermoplastic device worn for 5–10 minutes after removing the MAS guides the condyle back to its habitual position and is considered first-line treatment for decreased overjet and overbite.
4. Structured dental monitoring: Annual review appointments are essential for occlusal monitoring, device inspection, symptom reassessment, and device replacement planning.

Qualified dentists should provide oversight of oral appliance therapy in adult patients with obstructive sleep apnoea, to survey for dental-related side effects or occlusal changes and reduce their incidence.

(For the complete long-term care guide — including the full side effect timeline, predictors of greater occlusal change, and the evidence for each mitigation strategy — see our guide on Long-Term Care and Side Effects of Mandibular Advancement Splints: What Every Patient Should Know.)

Part 7: Special considerations

Primary snoring vs. OSA — why every snorer warrants investigation

Snoring and OSA are not the same condition. Primary snoring involves upper airway vibration without airway collapse, oxygen desaturation, or clinically significant sleep disruption. OSA involves recurrent partial or complete airway collapse with measurable oxygen desaturation and sleep fragmentation.

The two exist on a continuum, though. Primary snoring is not necessarily a stable, permanent condition — it likely sits at one end of a sleep-related breathing disorder (SRBD) spectrum, with OSA at the other. Emerging evidence implicates neurogenic pathology: the vibration trauma of chronic snoring may itself damage the tissues that protect the airway, potentially accelerating the progression from primary snoring to OSA.

Snoring volume is not a reliable diagnostic indicator. A quiet snorer can have severe OSA, and a thunderously loud snorer may have none. This is the fundamental reason why clinical history and partner reports, whilst useful, cannot replace objective sleep testing. (For the complete evidence-based analysis of primary snoring vs. OSA — including the risk factors that escalate one to the other and the systemic health stakes of untreated OSA — see our guide on Does Snoring Always Mean Sleep Apnoea? Understanding Primary Snoring vs. OSA.)

Teeth grinding in children — a paediatric clinical alert

Bruxism is not an adult-only condition. Sleep bruxism is most common in children, affecting 15–40% of children compared to 8–10% of adults. The most clinically important insight in paediatric bruxism research is the strong association between sleep bruxism and sleep-disordered breathing (SDB) in children.

One proposed mechanism is that rhythmic masticatory muscle activity (RMMA) in children may be an oromotor activity that helps reinstate airway patency following an obstructive respiratory event during sleep — the same airway-rescue mechanism documented in adults. Compelling evidence comes from adenotonsillectomy research: in a prospective study of children with obstructive symptoms due to adenotonsillar hypertrophy, the prevalence of bruxism was 25.7% before surgery and 7.1% after it (p = 0.02). This powerfully illustrates that, in children, bruxism driven by airway obstruction may resolve once the obstruction is treated.

Children with ADHD are at particularly elevated risk: a systematic review and meta-analysis published in JAMA Pediatrics found that ADHD was associated with an increased chance of bruxism with an odds ratio of 2.94. Any child presenting with habitual nocturnal grinding — especially combined with snoring, mouth breathing, or restless sleep — warrants multidisciplinary assessment rather than simply being fitted with a tooth guard. (For the complete paediatric guide — including the clinical distinctions between developmental grinding, sleep bruxism, and TMD in children — see our guide on Teeth Grinding in Children and Adolescents: Is It TMD or Sleep-Related Bruxism?.)

Part 8: Why integrated care at Smile Solutions matters

The clinical architecture that changes outcomes

Patients undergoing mandibular advancement device (MAD) therapy for obstructive sleep apnoea may experience changes in jaw position and altered occlusion, which could contribute to the development or exacerbation of TMD symptoms. This bidirectional risk — OSA treatment potentially affecting TMD, and TMD potentially limiting OSA treatment options — is precisely why integrated expertise across both disciplines is not a luxury. It is a clinical necessity.

Most Melbourne dental practices offer either occlusal splints or mandibular advancement devices, managed by a generalist dentist with no systematic screening for the other conditions. At Smile Solutions, our approach is different. With practitioners trained across dental sleep medicine and temporomandibular disorder management, a diagnostic protocol that integrates clinical jaw examination, airway screening, and sleep study referral, and a formal collaborative relationship with sleep medicine physicians for post-titration confirmation of device efficacy, you receive care that is calibrated to your complete clinical picture.

The technology matters too. Custom-made MADs show marginally greater AHI reduction than ready-made MADs, have longer wearing times and higher adherence rates, and generally have fewer side effects than ready-made MADs. Smile Solutions' use of CAD/CAM technology and 3D-printed nylon fabrication delivers superior fit accuracy, device durability, and patient comfort compared to traditional stone-cast and thermoforming methods — with the digital workflow enabling faster fabrication and permanent archivability of your records.

The correct splint for the correct diagnosis is the foundational principle of our approach. It is advisable and logical to treat obstructive sleep apnoea, TMD, and orofacial pain simultaneously from a clinical point of view, if these conditions coexist. At Smile Solutions, your personalised treatment plan is calibrated to address co-existing conditions simultaneously — not in isolated, sequential silos.

(For the complete patient journey at Smile Solutions — from initial consultation through titration, follow-up sleep testing, and long-term monitoring — see our guides on Getting Your Mandibular Advancement Splint at Smile Solutions: A Step-by-Step Patient Guide and Why Choose Smile Solutions for TMD, Bruxism, and Sleep Apnoea Treatment?.)

Frequently Asked Questions

Q1: What is the difference between TMD and TMJ?

"TMJ" refers to the temporomandibular joint itself — the hinge and sliding joint that connects your lower jaw to your skull. "TMD" (temporomandibular disorder) is the umbrella term for the group of conditions involving pain and/or dysfunction in that joint, the surrounding muscles, and associated structures. In everyday language, people often say "TMJ" when they mean TMD. Clinically, the distinction matters because TMD encompasses 12 distinct diagnoses — from myofascial muscle pain to internal disc derangement to degenerative joint disease — each with different treatment implications.

Q2: Can teeth grinding cause sleep apnoea, or does sleep apnoea cause teeth grinding?

Both directions are supported by evidence, and this is one of the most important insights in dental sleep medicine. OSA can drive sleep bruxism: when the airway collapses during sleep, your brain triggers arousal signals that activate the jaw muscles, causing grinding as a reflexive attempt to thrust the mandible forward and reopen the airway. Conversely, chronic bruxism can worsen TMD, which can alter jaw position and compromise airway geometry during sleep. The two conditions share risk factors and amplify each other, which is why all patients presenting with sleep bruxism should be screened for OSA, and vice versa.

Q3: Is a mandibular advancement splint the same as a nightguard?

No — and confusing the two can have serious clinical consequences. A nightguard (occlusal splint) is a passive protective device that cushions your teeth against grinding forces but does not advance the jaw or address the airway. A mandibular advancement splint (MAS) actively repositions your lower jaw forward during sleep, physically widening the upper airway to treat snoring and OSA. For patients with co-existing OSA and bruxism, a standard nightguard may actually worsen airway obstruction by altering mandibular posture. An MAS addresses both conditions simultaneously and is the clinically appropriate choice when OSA is present or suspected.

Q4: How do I know if I need a sleep study before getting a mandibular advancement splint?

If you snore habitually, experience daytime fatigue or unrefreshing sleep, have been told you stop breathing during sleep, or are being considered for an MAS for any reason, a sleep study is strongly recommended before the device is fabricated. A pre-treatment sleep study establishes your baseline AHI (the severity of your OSA), which determines the appropriate treatment pathway and provides the objective benchmark against which post-treatment efficacy is measured. Without it, there is no way to confirm whether the MAS is working at a therapeutic level. The AASM/AADSM Clinical Practice Guideline explicitly recommends follow-up sleep testing for all patients fitted with oral appliances.

Q5: How long does it take for a mandibular advancement splint to work?

Most patients begin to notice improvements in snoring and sleep quality within the first 2–4 weeks of wearing their MAS. However, the device typically requires 6–12 weeks of incremental titration to reach its optimal therapeutic position. The full clinical picture — including objective confirmation of AHI reduction — requires a follow-up sleep study performed with the device in situ after titration is complete. Some patients adapt quickly; others require more time and more gradual advancement. The titration process is individual and cannot be rushed without risking TMJ discomfort.

Q6: Can children be treated with a mandibular advancement splint?

MAS therapy is generally not appropriate for children and adolescents whose jaws are still growing, as the forces generated by mandibular advancement can interfere with craniofacial development. However, children with sleep bruxism and suspected sleep-disordered breathing should be evaluated by a sleep physician and, where relevant, an ENT specialist — because in many paediatric cases, the bruxism is driven by airway obstruction from enlarged tonsils or adenoids, and adenotonsillectomy may resolve both the airway problem and the grinding simultaneously. Paediatric TMD is managed conservatively with physiotherapy, behavioural strategies, and in some cases, soft splints.

Q7: What happens if I wear a mandibular advancement splint for many years?

Long-term MAS use produces progressive, measurable changes to the bite relationship — specifically, reductions in overjet and overbite, retroclination of upper incisors, and proclination of lower incisors. These changes are well-documented in the literature and do not plateau with time. They are manageable with conservative titration, morning jaw exercises, morning occlusal guides (AM aligners), and structured annual dental monitoring. The key is informed consent and proactive monitoring — patients who understand these changes and attend regular review appointments can maintain effective, safe MAS therapy over many years. Patients who are not monitored may experience progressive bite changes that become clinically significant.

Q8: I've been told I have TMD. Does that mean I can't use a mandibular advancement splint for my sleep apnoea?

Not necessarily. A systematic review and meta-analysis found that patients with pre-existing signs and symptoms of TMD do not experience significant exacerbation of symptoms using a MAD, and the presence of TMD does not appear to be a routine contraindication for MAD use in OSA management. However, active, severe TMD — particularly with significant disc displacement or acute joint pain — requires careful evaluation and may necessitate preliminary TMD management before MAS fabrication. Mild-to-moderate TMD, properly assessed, does not preclude MAS therapy. The key is comprehensive pre-treatment evaluation by a clinician with expertise in both conditions.

Key takeaways

1. TMD, bruxism, and OSA are a mechanistically interlocked clinical triad. They share anatomy, neurobiology, and risk factors, and each condition amplifies the others through bidirectional pathways. Treating any one in isolation — without screening for the others — is incomplete care.

2. Sleep bruxism is frequently an airway-rescue reflex, not a stress habit. When OSA drives grinding, treating only the grinding without addressing the airway fails you at a fundamental level. All patients with sleep bruxism should be screened for OSA.

3. Treating OSA can directly reduce TMD pain. A prospective cohort study demonstrated significant improvements in TMD pain and headache attributed to TMD after 18 months of OSA treatment — evidence that the pain-sleep amplification loop is real and clinically reversible.

4. A standard occlusal splint can worsen OSA. By increasing vertical dimension without advancing the mandible, a maxillary flat-plane splint can posteriorly rotate the jaw and reduce the posterior airway space. Prescribing a nightguard without OSA screening is not conservative management — it is incomplete management.

5. Custom-made MAS is the evidence-based standard. Pre-fabricated devices have lower efficacy, lower adherence, and more side effects than custom-made devices. The fabrication workflow — digital impressions, CAD/CAM design, 3D-printed nylon — directly determines device performance.

6. MAS and CPAP achieve comparable real-world health outcomes. CPAP achieves superior AHI reduction on paper, but higher MAS adherence offsets this difference in practice. For mild-to-moderate OSA, and for CPAP-intolerant patients at any severity, MAS is a clinically equivalent first-line option.

7. Long-term MAS use produces progressive occlusal changes. These changes are well-documented, manageable, and do not plateau. Conservative titration, morning jaw exercises, AM aligners, and structured annual monitoring are the evidence-based mitigation strategies.

8. Diagnosis must precede device selection. A sleep study before MAS fabrication, and a follow-up sleep study after titration, are non-negotiable components of responsible oral appliance care.

9. Children who grind their teeth should be screened for airway obstruction. Paediatric bruxism is frequently driven by sleep-disordered breathing, and adenotonsillectomy can resolve both the airway problem and the grinding in appropriately selected children.

10. Integrated dental sleep medicine expertise changes outcomes. The clinical architecture of care — combining TMD expertise, dental sleep medicine, CAD/CAM fabrication, and physician collaboration — is what separates comprehensive management from symptom suppression.

Conclusion

The convergence of TMD, bruxism, and obstructive sleep apnoea into a recognised clinical triad is one of the most important developments in dental sleep medicine over the past two decades. It reframes jaw pain not as a dental inconvenience but as a potential signal of systemic sleep-disordered breathing. It reframes teeth grinding not as a stress habit but as a possible airway-rescue reflex. And it reframes snoring not as a social nuisance but as the audible leading edge of a condition with serious cardiovascular, metabolic, and cognitive consequences.

The evidence is clear: these conditions must be assessed together, diagnosed accurately, and treated in an integrated fashion. If you arrive at Smile Solutions with jaw pain and a partner who complains about your snoring, you deserve more than a nightguard. You deserve a clinician who understands the triad, has the diagnostic tools to characterise it fully, and has the treatment repertoire to address it comprehensively.

That is the standard of clinical excellence this guide — and Smile Solutions — is built around.

If you're ready to take the next step, our experienced specialists are here to help. No referral is required. Call us on 13 13 96 or visit smilesolutions.com.au to arrange your personalised TMD and sleep treatment consultation at our heritage Manchester Unity Building, Level 1 and 10, 220 Collins Street, Melbourne CBD.

Smile Solutions has been providing comprehensive dental care from Melbourne's CBD since 1993. Located at the Manchester Unity Building, Level 1 and 10, 220 Collins Street, Smile Solutions brings together over 80 clinicians — including 25+ board-registered specialists — who have cared for over 300,000 patients. No referral is required to book a specialist appointment. Call 13 13 96 or visit smilesolutions.com.au to arrange your TMD and sleep treatment consultation.

References

• Zieliński, G., Pająk, A., & Wójcicki, M. "Global Prevalence of Sleep Bruxism and Awake Bruxism in Pediatric and Adult Populations: A Systematic Review and Meta-Analysis." Journal of Clinical Medicine, 2024. https://doi.org/10.3390/jcm13144259

• Sanders, A.E., et al. "Sleep Apnea Symptoms and Risk of Temporomandibular Disorder: OPPERA Cohort." Journal of Dental Research, 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3706181/

• Alessandri-Bonetti, A., Lobbezoo, F., Mangino, G., Aarab, G., & Gallenzi, P. "Obstructive Sleep Apnea Treatment Improves Temporomandibular Disorder Pain." Sleep and Breathing, 28(1): 203-209, 2024. https://doi.org/10.1007/s11325-023-02883-4

• Gotsopoulos, H., et al. "A Randomized, Controlled Study of a Mandibular Advancement Splint for Obstructive Sleep Apnea." American Journal of Respiratory and Critical Care Medicine, 163(6): 1455-1460, 2001. https://doi.org/10.1164/ajrccm.163.6.2004213

• Park, J.H., et al. "Efficacy and Adherence of Different Mandibular Advancement Device Designs in Treatment of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis." American Journal of Orthodontics and Dentofacial Orthopedics, 2025. https://doi.org/10.1016/j.ajodo.2025.01.006

• Pliska, B.T., Nam, H., Chen, H., Lowe, A.A., & Almeida, F.R. "Obstructive Sleep Apnea and Mandibular Advancement Splints: Occlusal Effects and Progression of Changes Associated with a Decade of Treatment." Journal of Clinical Sleep Medicine, 10(12): 1285-1291, 2014. https://doi.org/10.5664/jcsm.4278

• Ramar, K., et al. "Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015." Journal of Clinical Sleep Medicine, 11(7): 773-827, 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/

• Schiffman, E., et al. "Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications." Journal of Oral & Facial Pain and Headache, 28(1): 6-27, 2014.

• Al-Jewair, T., Shibeika, D., & Ohrbach, R. "Temporomandibular Disorders and Their Association with Sleep Disorders in Adults: A Systematic Review." Journal of Oral & Facial Pain and Headache, 35(1): 41-53, 2021.

• Balasubramaniam, R., et al. "Oral Appliance Therapy for Snoring and Obstructive Sleep Apnoea: A Practical Guide for Clinical Care." Australian Dental Journal, 2024. https://doi.org/10.1111/adj.13062

• Lee, Y.H., Lee, K.M., & Auh, Q.S. "Clinical, Psychological, and Hematological Factors Predicting Sleep Bruxism in Patients with Temporomandibular Disorders." Scientific Reports, 2025. https://www.nature.com/articles/s41598-025-03339-3

• Mdpi.com. "Relationship Between Bruxism and Obstructive Sleep Apnea: A Systematic Review of the Literature." Journal of Clinical Medicine, 14(14): 5013, 2025. https://doi.org/10.3390/jcm14145013

• Arrieta-Blanco, J.J., et al. (Arribas-Pascual et al.) "Umbrella Meta-Meta-Analysis of Physiotherapy Interventions for TMD." Journal of Clinical Medicine, 2023.

• Bartolucci, M.L., et al. "Dental and Skeletal Long-Term Side Effects of Mandibular Advancement Devices in Obstructive Sleep Apnea Patients: A Systematic Review with Meta-Regression Analysis." European Journal of Orthodontics, 41(1): 89-100, 2019.

• Pattipati, M., et al. "Comparison of Mandibular Advancement Device and Continuous Positive Airway Pressure in the Treatment of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis." Cureus, 2022.